Literature DB >> 29167176

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.

Maria Gavriatopoulou1, Efstathios Kastritis1, Ioannis Ntanasis-Stathopoulos1, Despina Fotiou1, Maria Roussou1, Magdalini Migkou1, Dimitrios C Ziogas1, Nikolaos Kanellias1, Evangelos Terpos1, Meletios Athanasios Dimopoulos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29167176     DOI： 10.1182/blood-2017-10-809293

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

1.  CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Authors:  Meisam Naeimi Kararoudi; Yuya Nagai; Ezgi Elmas; Marcelo de Souza Fernandes Pereira; Syed Abbas Ali; Philip Hollingsworth Imus; Darren Wethington; Ivan Marques Borrello; Dean Anthony Lee; Gabriel Ghiaur
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

2.  Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.

Authors:  Efstathios Kastritis; Maria Roussou; Maria Gavriatopoulou; Nikolaos Kanellias; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Dimitrios C Ziogas; Despina Fotiou; Ioannis Ntanasis-Stathopoulos; Ioanna Dialoupi; Stavroula Giannouli; Panagiotis Tsirigotis; Sossana Delimpasi; Despina Mparmparousi; Mairylin Spyropoulou-Vlachou; Aikaterini Xirokosta; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Blood Adv       Date:  2019-12-10

Review 3.  Daratumumab for the Treatment of Multiple Myeloma.

Authors:  Torben Plesner; Jakub Krejcik
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

Review 4.  Immunotherapy in Multiple Myeloma.

Authors:  Cinnie Yentia Soekojo; Melissa Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Cells       Date:  2020-03-03       Impact factor: 6.600

5.  Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Evangelos Terpos; María-Victoria Mateos; Sonja Zweegman; Gordon Cook; Michel Delforge; Roman Hájek; Fredrik Schjesvold; Michele Cavo; Hartmut Goldschmidt; Thierry Facon; Hermann Einsele; Mario Boccadoro; Jesús San-Miguel; Pieter Sonneveld; Ulrich Mey
Journal:  Hemasphere       Date:  2021-02-03

Review 6.  CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.

Authors:  Niels W C J van de Donk; Saad Z Usmani
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

7.  Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.

Authors:  Laurens E Franssen; Inger S Nijhof; Chad C Bjorklund; Hsiling Chiu; Ruud Doorn; Jeroen van Velzen; Maarten Emmelot; Berris van Kessel; Mark-David Levin; Gerard M J Bos; Annemiek Broijl; Saskia K Klein; Harry R Koene; Andries C Bloem; Aart Beeker; Laura M Faber; Ellen van der Spek; Reinier Raymakers; Pieter Sonneveld; Sonja Zweegman; Henk M Lokhorst; Anjan Thakurta; Xiaozhong Qian; Tuna Mutis; Niels W C J van de Donk
Journal:  Oncotarget       Date:  2018-09-21

Review 8.  Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.

Authors:  Laurens E Franssen; Claudia A M Stege; Sonja Zweegman; Niels W C J van de Donk; Inger S Nijhof
Journal:  J Clin Med       Date:  2020-04-22       Impact factor: 4.241

Review 9.  CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies.

Authors:  Fabio Morandi; Irma Airoldi; Danilo Marimpietri; Cristiano Bracci; Angelo Corso Faini; Roberto Gramignoli
Journal:  Cells       Date:  2019-11-27       Impact factor: 6.600

Review 10.  Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.

Authors:  Jakub Radocha; Niels W C J van de Donk; Katja Weisel
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.